Fig. 1From: Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case reportTimeline of palovarotene dosing in the open label phase of the PVO-1A-202B trial. Flare-up dosing, flare site, and fracture events are notedBack to article page